140 related articles for article (PubMed ID: 27008827)
1. [Some case reports which suggest correlation between biologics and leprosy, Mini-symposium on problems on leprosy].
Ishida Y
Nihon Hansenbyo Gakkai Zasshi; 2016 Jan; 84(3):133-7. PubMed ID: 27008827
[TBL] [Abstract][Full Text] [Related]
2. Biologics in Leprosy: A Systematic Review and Case Report.
Cogen AL; Lebas E; De Barros B; Harnisch JP; Faber WR; Lockwood DN; Walker SL
Am J Trop Med Hyg; 2020 May; 102(5):1131-1136. PubMed ID: 32157993
[TBL] [Abstract][Full Text] [Related]
3. [Biologics and mycobacterial diseases].
Tsuyuguchi K; Matsumoto T
Kekkaku; 2013 Mar; 88(3):337-53. PubMed ID: 23672175
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW
J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538
[TBL] [Abstract][Full Text] [Related]
5. Biologics for the treatment of autoimmune renal diseases.
Holdsworth SR; Gan PY; Kitching AR
Nat Rev Nephrol; 2016 Apr; 12(4):217-31. PubMed ID: 26949177
[TBL] [Abstract][Full Text] [Related]
6. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
Wu N; Lee YC; Shah N; Harrison DJ
Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
[TBL] [Abstract][Full Text] [Related]
7. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
8. Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University Psoriasis Registry.
Bayaraa B; Imafuku S
J Dermatol; 2019 May; 46(5):389-398. PubMed ID: 30861182
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of biologic treatments in Familial Mediterranean Fever.
Akgul O; Kilic E; Kilic G; Ozgocmen S
Am J Med Sci; 2013 Aug; 346(2):137-41. PubMed ID: 23276893
[TBL] [Abstract][Full Text] [Related]
10. Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data.
Sugiyama N; Kawahito Y; Fujii T; Atsumi T; Murata T; Morishima Y; Fukuma Y
Clin Ther; 2016 Jun; 38(6):1359-1375.e1. PubMed ID: 27101816
[TBL] [Abstract][Full Text] [Related]
11. Wide difference in biologics usage and expenditure for the treatment of patients with rheumatoid arthritis in each prefecture in Japan analyzed using "National Database of Health Insurance Claims and Specific Health Checkups of Japan".
Kamata Y; Minota S
Rheumatol Int; 2018 Apr; 38(4):663-668. PubMed ID: 29204683
[TBL] [Abstract][Full Text] [Related]
12. Why Do Patients with Chronic Inflammatory Rheumatic Diseases Discontinue Their Biologics? An Assessment of Patients' Adherence Using a Self-report Questionnaire.
Betegnie AL; Gauchet A; Lehmann A; Grange L; Roustit M; Baudrant M; Bedouch P; Allenet B
J Rheumatol; 2016 Apr; 43(4):724-30. PubMed ID: 26879361
[TBL] [Abstract][Full Text] [Related]
13. Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort.
Piga M; Chessa E; Ibba V; Mura V; Floris A; Cauli A; Mathieu A
Autoimmun Rev; 2014 Aug; 13(8):873-9. PubMed ID: 24840285
[TBL] [Abstract][Full Text] [Related]
14. Use of biologics in SLE: a review of the evidence from a clinical perspective.
Aytan J; Bukhari MA
Rheumatology (Oxford); 2016 May; 55(5):775-9. PubMed ID: 26424838
[TBL] [Abstract][Full Text] [Related]
15. Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.
Norlin JM; Carlsson KS; Persson U; Schmitt-Egenolf M
BioDrugs; 2015 Dec; 29(6):389-98. PubMed ID: 26670179
[TBL] [Abstract][Full Text] [Related]
16. Use of anti-tumor necrosis factor biologics in the treatment of rheumatoid arthritis does not change human T-lymphotropic virus type 1 markers: a case series.
Umekita K; Umeki K; Miyauchi S; Ueno S; Kubo K; Kusumoto N; Takajo I; Nagatomo Y; Okayama A
Mod Rheumatol; 2015 Sep; 25(5):794-7. PubMed ID: 24252020
[TBL] [Abstract][Full Text] [Related]
17. Restarting biologics and management of patients with flares of inflammatory rheumatic disorders or psoriasis during active tuberculosis treatment.
Cantini F; Prignano F; Goletti D
J Rheumatol Suppl; 2014 May; 91():78-82. PubMed ID: 24789004
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of Phototherapy in the Age of Biologics.
Calzavara-Pinton P; Zanca A; Arisi M; Rossi MT; Zane C; Venturini M; Ortel B
Dermatology; 2018; 234(5-6):166-172. PubMed ID: 30205372
[TBL] [Abstract][Full Text] [Related]
19. [Scientific and rational usage of biologics for the rheumatic diseases: a step forward comments on Chinese consensus of etanercept for rheumatoid arthritis and ankylosing spondylitis (2013 edition)].
Zhao Y
Zhonghua Yi Xue Za Zhi; 2013 May; 93(18):1361-2. PubMed ID: 24025499
[No Abstract] [Full Text] [Related]
20. Inflammatory cytokine levels, disease activity, and function of patients with rheumatoid arthritis treated with combined conventional disease-modifying antirheumatic drugs or biologics.
Osiri M; Wongpiyabovorn J; Sattayasomboon Y; Thammacharoenrach N
Clin Rheumatol; 2016 Jul; 35(7):1673-81. PubMed ID: 27188857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
